The growing landscape of FLT3 inhibition in AML
Dec 6, 2019 · Midostaurin and gilteritinib are FLT3 inhibitors that have been recently approved for use in FLT3 -mutant acute myeloid leukemia (AML). These approved drugs represent a new …
Deletions in FLT-3 juxtamembrane domain define a new class of ...
Apr 29, 2021 · Deletion of individual residues in the FLT-3 juxtamembrane domain, such as Q575Δ, can be activating similar to the classic ITD mutation. A systematic analysis informed …
Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients with acute …
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and …
Mutations in FLT3 are the most common genetic alteration in AML, identified in approximately one third of newly diagnosed patients. FLT3 internal tandem duplication mutations (FLT3- ITD) are …
Identification of Driver and Passenger Mutations of FLT3 by High ...
We used a combined genetic and functional approach to evaluate a series of candidate mutations in the receptor tyrosine kinase FLT3 that were identified in patients with AML.
Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 ...
Nov 15, 2022 · In vitro studies indicated patients with FLT3 deletion mutations and FLT3-ITD outside the JMD and TKD1 regions might be ought to be treated with FLT3 inhibitors. Our new …
FLT3 targeting in the modern era: from clonal selection to
Dec 19, 2023 · Modern targeting of FLT3 with inhibitors has improved clinical outcomes and FLT3 inhibitors have been incorporated into the treatment of AML in all phases of the disease, …
The mutational spectrum of FLT3 gene in acute lymphoblastic
Jul 8, 2019 · Mutations in FMS-like tyrosine kinase 3 (FLT3) gene occur frequently in acute myeloid leukemia (AML) and are rare in acute lymphoblastic leukemia (ALL). We aimed to …
Full article: The importance of FLT3 mutational analysis in acute ...
Nov 22, 2017 · Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in …
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked ...
Jan 9, 2020 · FLT3 inhibitors are divided into first generation multi-kinase inhibitors (such as sorafenib, lestaurtinib, midostaurin) and next generation inhibitors (such as quizartinib, …